Table 2. Comparison of Medication Administered along with Tocilizumab between Patients with and without Anti-HBc.
| Medications | Patients with anti-HBc (n=15) | Patients without anti-HBc (n=24) | p value |
|---|---|---|---|
| Glucocorticoid | 14 (93.3) | 21 (87.5) | 0.999 |
| Cumulative glucocorticoid dosage (mg)* | 1015.0 (506.3–1760.0) | 1295.0 (519.1–3073.8) | 0.419 |
| Cumulative glucocorticoid dosage within the first 6 months (mg)* | 775.0 (340.0–905.0) | 800.0 (452.5–1061.3) | 0.523 |
| Methotrexate | 11 (73.3) | 17 (70.8) | 0.999 |
| Cumulative methotrexate dosage (mg)† | 557.1 (294.7–940.7) | 689.6 (444.6–1156.8) | 0.458 |
| Cumulative methotrexate dosage within the first 6 months (mg)† | 338.6 (266.1–490.0) | 316.4 (240.0–379.8) | 0.312 |
| Leflunomide | 0 (0.0) | 2 (8.3) | 0.514 |
| Hydroxychloroquine | 1 (6.7) | 6 (25.0) | 0.216 |
| Sulfasalazine | 3 (20.0) | 7 (29.2) | 0.711 |
| Tacrolimus | 1 (6.7) | 2 (8.3) | 0.999 |
Anti-HBc, positive antibody to HBV core antigen.
Values are expressed as the median (interquartile range) or number (percentage).
*The cumulative glucocorticoid dosage was represented in prednisolone equivalent dosage and was calculated in those treated with glucocorticoids, †The cumulative methotrexate dosage was calculated in those treated with methotrexate.